PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25191794-6 2014 The chemical synthesis of highly stable linker-drugs and the modification of cysteine residues of engineered site-specific antibodies resulted in a homogeneous ADC with increased therapeutic activity compared to the clinically approved ADC, trastuzumab-MCC-DM1. Cysteine 77-85 immunoglobulin heavy diversity 1-7 Homo sapiens 257-260